1. Introduction {#s0005}
===============

Fructus Forsythiae, the fruit of *Forsythia suspense* (Thunb.) Vahl (Oleaceae), is a well-known traditional Chinese medicine (TCM) and is widely used for the treatment of infections such as acute nephritis, pharyngitis, pyrexia erysipelas, ulcer, tonsillitis and gonorrhea [@bb0005]. Remarkably, Fructus Forsythiae was recommended for the treatment and prevention of severe acute respiratory syndrome (SARS) [@bb0010] that may be caused by the inappropriate activation of complement systems [@bb0015]. So, it is hopeful to search for anticomplementary components from Fructus Forsythiae. Its main bioactive components were identified as phenylethanoid glycosides, lignans and flavonols according to phytochemical investigations [@bb0020], [@bb0025]. Forsythoside A (FTA) is one of the main phenylethanoid glycosides from Fructus Forsythiae, which possesses strong antimicrobial, antioxidant and antiviral activities [@bb0030], [@bb0035]. The chemical structure of FTA is composed of three chemical moieties including aglycone (caffeic acid), phenylethanoid aglycone (hydroxytyrosol), and sugar moieties. Its content was approximately 8% in total, which was much higher than other ingredients, but its absolute oral bioavailability was approximately 0.5%, which was significantly lower [@bb0040]. However, FTA bioavailability demonstrated a more direct relationship with the pharmacological efficacy of forsythia extract than the representative ingredients in lignans such as phillyrin [@bb0045], [@bb0050]. According to the reports, the mechanism of FTA intestinal absorption was passive diffusion and involved paracellular transport, which is mainly governed by tight junctions [@bb0055], and FTA may be a substrate of CYP3A4, CYP2C9, CYP1A2, UGT1A6, UGT1A3, UGT1A1 and UGT1A9 for in vitro metabolism in Sprague--Dawley rat liver microsomes [@bb0060]. Moreover, most herbal medicines are orally administered, and their active components are therefore brought into contact with intestinal microflora in the alimentary tract, which are mostly composed of anaerobes [@bb0065]. Some of them are transformed by intestinal bacteria before absorption from the gastrointestinal tract. Studies on herbal component metabolism by intestinal microflora are of a great importance to understanding their biological effects [@bb0070], [@bb0075]. So far, there is no report on the metabolism of FTA by intestinal bacteria. In addition, most studies on bioactivity of FTA were focused on antibacterial and antiendotoxin activities but not anticomplementary activity. In our study, FTA was anaerobically incubated with human fecal microflora, its metabolites were identified via UPLC--Q-TOF/MS and pharmacological effects were tested.

2. Experimental {#s0010}
===============

2.1. Materials and methods {#s0015}
--------------------------

### 2.1.1. Materials and reagents {#s0020}

General anaerobic medium broth (GAM broth) was purchased from Shanghai Kayon Biological Technology Co., Ltd (Shanghai, China). Sheep erythrocytes, rabbit erythrocytes and anti-sheep erythrocyte antibodies were purchased from Shanghai Fortune Biological Technological Co., Ltd (Shanghai, China). Heparin (sodium salt, 160 IU/mg) was purchased from China National Medicines Co., Ltd (Shanghai, China). Normal human serum was obtained from healthy adult donors. Guinea pig serum was obtained from healthy guinea pigs from the Laboratory Animal Research Center of Fudan University. *Escherichia coli* (ATCC8739), *Staphylococcus aureus* (ATCC25923), *Klebsiella pneumonia* (ATCC13883) and *Candida albicans* (ATCC10231) were provided by the laboratory of Dr. Mei Ge.

Forsythoside A was purchased from Shanghai Winherb Medical Technology Co., Ltd.; hydroxytyrosol, caffeic acid and 3, 4-dihydroxybenzenepropionic acid were purchased from J&K Chemical Ltd.; HPLC-grade acetonitrile and methanol were purchased from Merck. Ultrapure water was prepared with a Milli-Q water purification system (Millipore). All of the other chemicals and reagents were of analytical grade.

### 2.1.2. Instrumentation {#s0025}

Analyses were performed on a commercially available ACQUITY UPLC system connected online to an ACQUITY TQD triple quadrupole mass spectrometer (Waters Corp., Milford, MA, USA) with a conditioned autosampler at 4 °C. All of the data were collected using MassLynx software. The separation was performed on a Syncronis C~18~ column (100 × 2.1 mm i.d., 1.7 μm; Thermo, USA) with the column temperature set to 35 °C. The mobile phase consisted of (A) ultra-pure water containing 0.1% formic acid and (B) acetonitrile using a gradient elution of 5--10% B at 0--1.5 min, 10--25% B at 1.5--8 min, 25--45% B at 8--13 min, 45--100% B at 13--18 min, 100% B at 18--21 min, and 100--5% B at 21--24 min. The flow rate was 0.4 ml/min, and the injection volume was 5 μl.

The MS instrument consisted of a Waters Synapt™ QTOF/MS (Waters Corp., Milford, MA, USA). Ionization was performed in the negative electrospray (ESI) mode. Mass range was set at m/z 50--1000 Da with a 0.28 s scan time. The ESI source was operated in negative ionization mode with capillary voltage at 2.0 kV. Source and desolvation temperatures were set at 120 and 350 °C, respectively. Nitrogen was used as desolvation and cone gas with a flow rate of 700 and 50 l/h, respectively. For accurate mass measurement, the data were centroided during acquisition using an external reference (LockSpray™) comprising a 2 μg/ml solution of leucine--enkephalin (purchased from J&K Chemical Ltd.), which was infused continuously into the ESI source at a rate of 400 μl/min via a syringe pump. The data were processed using MassLynx™ 4.1 software (Waters Corp., Milford, MA, USA).

2.2. FTA metabolism in human intestinal bacteria in vitro {#s0030}
---------------------------------------------------------

Fresh fecal samples were obtained from 10 healthy volunteers (five male, five female, 22 to 50 years of age), who gave informed written consent to the study protocol. The volunteers had no history of gastrointestinal disorders and had not taken antibiotics for at least three months prior to the study. The fresh fecal mixture samples were immediately homogenized with 25 times of GAM broth. The sediments were removed by filtration through three pieces of gauze. The suspension was incubated at 37 °C in an anaerobic incubator in which the air had been replaced with a gas mixture (H~2~ 5%, CO~2~ 10%, N~2~ 85%). In total, 4 mg FTA was added to the human fecal suspension (10 ml), and the mixture was incubated at 37 °C in an anaerobic incubator for 24 h. The cultured mixture was removed and extracted with water saturated n-butanol. The extract was evaporated, and the residue was dissolved in methanol (0.5 ml) and analyzed with UPLC--Q-TOF/MS.

2.3. Anti-complement activity through the classical and the alternative pathways {#s0035}
--------------------------------------------------------------------------------

Based on our previous described method [@bb0080], the classical and alternative complement pathway-inhibiting properties of FTA and its metabolites were investigated. The data were reported in CH~50~ and AP~50~ to indicate the concentrations that resulted in 50% inhibition of sheep erythrocytes and the concentrations that resulted in 50% rabbit erythrocyte hemolysis inhibition, respectively. Heparin sodium salt was used as the positive control.

2.4. Antimicrobial activity by the agar disc-diffusion method minimal inhibitory concentration (MIC) determination {#s0040}
------------------------------------------------------------------------------------------------------------------

The antimicrobial activity assay was performed on FTA and its metabolites with five test bacterial strains, and three replicates were performed for all of the samples. The positive controls were levofloxacin for bacteria and nystatin dehydrate for fungus, and the negative control was sterile distilled water. The antimicrobial effect of all of the samples was assessed in petri dishes with 20 ml nutrient agar plus 0.2 ml microorganism suspension (10^8^  CFU/ml, O.D 0.1, λ = 590 nm). Once the agar had solidified, 200 μl of each sample and sterile distilled water (negative control) was added to wells that were 3 mm in diameter. The plates were incubated at 37 °C for 24 h, and the inhibition halos were evaluated (mm). The antimicrobial effect was determined by measuring the inhibition halos that formed around the wells [@bb0085], [@bb0090].

The MIC value was determined by the dilution method according to the National Committee for Clinical Laboratory Standards [@bb0095]. The active samples and positive controls were dissolved in dimethyl sulfoxide at a concentration of 3200 μg/ml. Twofold serial dilutions of the solution were then prepared (3200, 1600, 800, down to 6.25 μg/ml). Nutrient broth was prepared with 1% test bacteria strains (10^8^  CFU/ml, O.D 0.1, λ = 590 nm). In total, 10 concentrations of each sample × three test bacterial strains × three replicate wells were performed in sterile round-bottom 96-well plates by comparing the sample with the non-inoculated nutrient broth. Inoculated nutrient broth (0.9 ml) and sample (0.1 ml) were placed into each well, and the plates were incubated at 37 °C for 24 h. MIC values were determined as the lowest concentration that inhibited visible bacterial growth as detected by the unaided eye.

2.5. Antiendotoxin effect of FTA and its metabolites by the gel clot limulus amoebocyte lysate (LAL) assay {#s0045}
----------------------------------------------------------------------------------------------------------

The LAL assay was performed in duplicate using commercial LAL reagent containing clotting enzyme (Zhanjiang A & C Biological Ltd., Guangdong, China). The assay was performed in pyrogen-free test tubes, to which 0.1 ml of test sample serial dilutions (1000, 500, down to 7.8 μg/ml) and 0.1 ml LAL reagent were added. The reaction solution was mixed thoroughly and placed immediately in a noncirculating water bath at 37 °C ± 1 °C for 60 ± 2 min. At the end of the incubation period, the test tubes were examined by 180° inversion for the presence of a stable solid clot. If a gel had formed and remained intact in the bottom of the reaction tube after inversion, the test was positive. The test was considered negative if a gel formed but broke or collapsed when inverted. Endotoxin standard (*E. coli* strain O111:B4, 0.125 EU/ml) and pyrogen-free LAL reagent water, both provided by the manufacturer, were used as controls [@bb0100].

3. Results {#s0050}
==========

3.1. Metabolic processing of FTA by human intestinal bacteria in vitro {#s0055}
----------------------------------------------------------------------

FTA was anaerobically incubated with a human fecal bacterial mixture, and the metabolic samples incubated at 6, 12 and 24 h were extracted with water-saturated n-butanol and analyzed by UPLC--Q-TOF/MS as demonstrated in [Fig. 1](#f0010){ref-type="fig"} . In total, three peaks were observed compared with the blank sample that only contained GAM and the standard FTA solution, and their time courses were determined as demonstrated in [Fig. 2](#f0015){ref-type="fig"} . FTA was converted to M1 and M3 at the initial time of 6 h, and M1 was increased with the incubated temporal variation. M3 degraded after incubation for 6 h, and M2 was converted at the same time. The content change between M2 and M3 was exactly opposite, indicating a mutual transformation between these two metabolites.Fig. 1TIC chromatograms of FTA incubated with human intestinal bacteria.Fig. 2Time courses of FTA production over 24 h after incubation with human intestinal bacteria. The data are presented as the mean ± SD.

3.2. Identification of FTA metabolites {#s0060}
--------------------------------------

FTA metabolites M1--M3 were analyzed by UPLC--MS, which is demonstrated in [Table 1](#t0005){ref-type="table"} . The negative electrospray mass spectrum of FTA revealed a \[M--H\]^−^ ion at m/z 623. The full mass of M3, which was detected at 2.83 min, gave a \[M--H\]^−^ ion at m/z 179, indicating the loss of glucopyranose, rhamnose and C~8~H~10~O~3~ from FTA to form caffeic acid (CA). The molecular ion of M1 \[M--H\]^−^ was 153, indicating the loss of glucopyranose, rhamnose and CA from FTA to form hydroxytyrosol (HT). The \[M--H\]^−^ ion of M2 was at m/z 181, indicating the hydrogenation reaction of CA to form 3,4-dihydroxybenzenepropionic acid (DCA). To further confirm the chemical structure, three metabolites were identified by comparing the retention times and UV spectra with reference substances based on MS data. Those data are summarized in [Table 1](#t0005){ref-type="table"}, deglycosylated and hydrogenated metabolites were present with human fecal incubation.Table 1Retention time (RT), ion mass peaks and peak area of FTA and its metabolites.No.RT (min)\[M --H\]^−^ m/zMetabolite nameFormulaArea (%)Parent Compound5.58623.1990FTAC~29~H~36~O~15~2.75M11.80153.0545HTC~8~H~10~O~3~0.93M22.73181.0509DCAC~9~H~10~O~4~0.16M32.83179.0335CAC~9~H~8~O~4~0.47

3.3. FTA metabolism with human intestinal bacteria {#s0065}
--------------------------------------------------

Based on the results above, FTA metabolism by human intestinal bacteria was proposed to function as follows ([Fig. 3](#f0020){ref-type="fig"} ). FTA was first desugared to form CA and large amounts of HT, and CA was further hydrogenated to form DCA.Fig. 3The possible metabolic pathway of FTA incubated with human intestinal bacteria.

3.4. Classical and alternative anticomplementary pathway activity {#s0090}
-----------------------------------------------------------------

The effect of FTA and its metabolites on guinea pig complement activation through the classical pathway was examined in 1:40 diluted guinea pig serum, and heparin sodium was used as the positive control. The percent of activation that 1:40 diluted guinea serum occurred in the classical pathway was 98.34 ± 5.23% in the complement control group. The percentage of activation that 1:10 diluted normal human serum occurred in the alternative pathway was 97.26 ± 7.85% in the complement control group. As [Table 2](#t0010){ref-type="table"} demonstrates, FTA demonstrated no anticomplementary activity for either the classical pathway or the alternative pathway. HT, CA and DCA all exhibited complement modulation properties in a dose-dependent manner. The CH~50~ were 0.096 ± 0.007 mg/ml, 0.321 ± 0.011 mg/ml and 0.923 ± 0.037 mg/ml for HT, DCA and CA, respectively. In the AP~50~ assay, the concentrations that resulted in 50% hemolysis inhibition of rabbit erythrocytes were 0.121 ± 0.012 mg/ml for HT, 0.427 ± 0.023 mg/ml for DCA and 1.038 ± 0.131 mg/ml for CA, respectively. HT demonstrated the most significant activity comparable to the positive inhibitor (heparin sodium, CH~50~  = 0.068 ± 0.002 mg/ml; AP~50~  = 0.086 ± 0.003 mg/ml).Table 2Anticomplementary activity of FTA and its metabolites by human intestinal bacteria.SampleCH~50~ (mg/ml)[a](#tf0005){ref-type="table-fn"}AP~50~ (mg/ml)[a](#tf0005){ref-type="table-fn"}FTANE[b](#tf0010){ref-type="table-fn"}NEHT0.096 ± 0.0070.121 ± 0.012DCA0.321 ± 0.0110.427 ± 0.023−CA0.923 ± 0.0371.038 ± 0.131Heparin sodium0.068 ± 0.0020.086 ± 0.003[^1][^2]

3.5. Determination of the antimicrobial activity of FTA and its metabolites {#s0070}
---------------------------------------------------------------------------

The primary antimicrobial screening was performed using the agar well diffusion method. The antimicrobial activity of FTA and its metabolites was compared with levofloxacin and nystatin dihydrate as standard antibiotics. As demonstrated in [Table 3](#t0015){ref-type="table"} , none of the tested samples exhibited any activity against *C. albicans* and *K. pneumonia*, but some of them possessed inhibitory activity against *E. coli* and *S. aureus*. HT demonstrated inhibitory effects against the Gram-positive bacteria *S. aureus* and the Gram-negative bacteria *E. coli*, while FTA and DCA were limited to *S. aureus*. The MIC values of FTA, HT and DCA against the bacteria are summarized in [Table 4](#t0020){ref-type="table"} . HT displayed the highest antimicrobial activity overall followed by FTA and DCA.Table 3Antimicrobial activity of FTA and its metabolites by human intestinal bacteria.SamplesZone of inhibition (cm)*E. coliS. aureusK. pneumoniaC. albicans*FTANE[a](#tf0015){ref-type="table-fn"}0.8NENECANENENENEHT1.21.6NE −NEDCANE1.1NENELevofloxacin2.82.32.1NENystatin DihydrateNENENE2.2[^3]Table 4MIC of FTA and its metabolites by human intestinal bacteria.SamplesMIC (μg/ml)*E. coliS*. *aureus*FTANE[a](#tf0020){ref-type="table-fn"}50HT5025DCANE50Levofloxacin0.11.5[^4]

3.6. Antiendotoxin effect of FTA and its metabolites {#s0075}
----------------------------------------------------

The antiendotoxin effect was determined by the Gel clot LAL assay in vitro. As the results presented in [Table 5](#t0025){ref-type="table"} , FTA and CA were invalid even at the maximal concentration. However, HT and DCA were still effective when diluted four and three times, respectively. HT possessed the highest antiendotoxin effect among the four compounds.Table 5Antiendotoxin effect of FTA and its metabolites by human bacteria.SamplesTubes no.11/21/41/81/161/321/641/128PositiveNegativeFTA+ ++ ++ ++ ++ ++ ++ ++ ++ +− −CA+ ++ ++ ++ ++ ++ ++ ++ ++ +− −HT− −− −− −− −+ ++ ++ ++ ++ +− −DCA− −− −− −+ ++ ++ ++ ++ ++ +− −

4. Discussion {#s0080}
=============

FTA, one of the main, most abundant active ingredients in Fructus Forsythiae, had low bioavailability. There were many physiological factors such as bile, intestinal microflora, and the gastrointestinal tract pH, which would be related to drug bioavailability [@bb0105]. According to the present study, after oral administration, FTA was first metabolized into CA and HT in anaerobic conditions, and then CA was converted to DCA by human fecal bacteria. The incubation process as well as the activity tests are under 37 °C or at low temperatures due to FTA instability at high temperature. Fortunately, no metabolites in our study was found (Figure not given) when FTA was incubated with blank that only contained GAM. Accordingly, the intestinal bacterial metabolism played an important role in the generation of three metabolites. FTA was proved to deglycosylated to CA and HT under the existence of glycosidase in the intestinal microflora. The same metabolic behavior was observed in naringin [@bb0110] and anthocyanin metabolism [@bb0115]. Hydrogenation also played an important role in CA metabolism in our study. These results were different from the Parkar\'s report [@bb0120], which demonstrated that CA may be metabolized into 3-hydroxyphenylpropionic acid and DCA mainly when incubated for 24 h with human fecal bacteria. This difference may due to different substrate concentrations or the presence of HT during the metabolic process.

So far, there is no report on the anticomplementary effect of FTA. The anticomplementary activities of phenylethanoid glycosides from *Monochasma savatieri* have previously been investigated [@bb0125]. In the present study, HT, as a main human intestinal bacteria-derived metabolite of FTA, demonstrated considerable anticomplementary activity compared with the positive control drug heparin sodium for the first time. HT is present in olive oil mainly as secoiridoid derivative, and it is the most active polyphenol from olive tree leaves, olive pulp and olive oil [@bb0130]. Interestingly, previous reports indicated that extracts of olive (*Olea europaea* L., Oleaceae) leaves demonstrated anticomplementary activity [@bb0135]. Accordingly, HT was indispensable in the anticomplementary effect of olive leaves. Conversely, the metabolite CA had a moderate effect to inhibit the classical and alterative pathways of the complement system, which is consistent with the previous report on the anticomplementary effect study of compounds from *Gnaphalium affine* D. Don [@bb0140].

In our study, FTA demonstrated inhibition against the Gram-positive bacteria *S. aureus* but no effect against the Gram-negative bacteria *E. coli* and *K. pneumonia* as well as *C. albicans*. The results indicated that *S. aureus* was the most susceptible to FTA among the four strains tested. HT possessed the highest antibacterial activity against the Gram-positive bacteria *S. aureus* and the Gram-negative bacteria *E. coli*. This result was consistent with what has been reported by Papadopoulou [@bb0145]. Other phenolic compounds have also demonstrated good activity against *S. aureus* such as epigallocatechin-3-O-gallate [@bb0150] and oleuropein [@bb0155]. DCA, a major metabolite, had the same antibacterial effect against *S. aureus* as FTA, which supports that phenylpropionic acid was more active against Gram-positive bacteria [@bb0160]. Characterization of the interaction between these antimicrobial compounds and their target sites also need to be further studied.

LAL assays are the most sensitive assays that are currently known for endotoxin [@bb0165]. Three types of LAL endotoxin testing methods (the gel-clot method, the chromogenic method, and the turbidimetric method) have been approved by the United States Pharmacopeia for the evaluation of end-product injectable drugs, medical devices, and raw materials [@bb0170]. The gel-clot method is thought of as the most accurate and sensitive procedure for determining endotoxin content because fewer false-positive and false-negative results are observed when that method is used [@bb0175]. Our study reveals that among FTA and its intestinal bacterial metabolites, HT and DCA had an antagonistic effect against endotoxin. DCA, a possible metabolite of CA containing the o-dihydroxyl structure, expressed higher antiendotoxin, anticomplementary and antibacterial effects than CA. Previous results suggested that the olefinic double bond in CA is an important factor for enhancing antioxidant activity [@bb0180]. Thus, it is likely that the 2,3-double bond of CA is critical for the pharmacodynamic expression of DCA.

DCA was reportedly found in human plasma as a metabolite of CA after dietary supplementation and may have been formed by intestinal bacteria [@bb0185]. Wang et al. [@bb0190] also demonstrated that HT and CA were identified as two major metabolites of echinacoside (a typical phenylethanoid glycoside) in rat urine and feces samples. What\'s more, anticomplementary and antiendotoxin properties of HT and DCA were determined for the first time in our study. Therefore, both DCA and HT were considered to be possible and effective metabolites in the body after oral administration of phenylethanoid glycosides such as FTA. The present result indicated that the biological activities were increased when FTA was metabolized to HT and DCA by human intestinal bacteria, which were coincident with the previous report that the intestinal flora played an important role in the metabolism of orally administered or bile-excreted compounds [@bb0195]. Herbal components should be transformed to bioactive compounds by intestinal bacteria and to perform the pharmacological action of herbal medicines [@bb0200], [@bb0205]. This conclusion might help explain that FTA demonstrated a positive correlation between dose and biological activity in *Forsythia suspense* [@bb0210].

5. Conclusion {#s0085}
=============

Our results demonstrated that the presence of intestinal bacteria played an important role in FTA metabolism after oral administration. The metabolic process is involved in hydrolytic reactions and the generation of non-polar low-molecular-weight byproducts, and FTA was accompanied by active metabolites. The results indicated that the pharmacological effects of FTA may be dependent on the metabolism of FTA by intestinal bacteria, which also clarified the low FTA bioavailability. However, further studies should be performed to elucidate anticomplementary and antimicrobial activity in vivo as well as the mechanism of action related to pharmacological activity.
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[^1]: The data are expressed as the mean ± SD of independent experiments performed in triplicate.

[^2]: NE denotes that this compound has no inhibitory effect at the maximal concentration tested.

[^3]: NE denotes that this compound has no inhibitory effect at the maximal concentration tested.

[^4]: NE denotes that this compound has no inhibitory effect at the maximal concentration tested.
